Does a failed head-to-head block approval?

No. Approval is assessed largely against placebo-controlled evidence, which REDEFINE 1 and 2 provide. A comparative trial answers a commercial question.

When is the FDA decision expected?

Company guidance points to the fourth quarter of 2026. No PDUFA date has been publicly confirmed.

Is CagriSema available in the UK?

No. It holds no MHRA authorisation, and a US approval would not change that.

Research & Regulatory News

CagriSema After REDEFINE 4

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-234 cited sources

CagriSema was filed with the FDA in December 2025 on the REDEFINE programme, with a decision expected in the fourth quarter of 2026. REDEFINE 4's failure to demonstrate non-inferiority against tirzepatide does not by itself block approval, because approval is assessed against placebo-controlled evidence.

Key facts

Filed with FDA: December 2025
Supporting trials: REDEFINE 1 and REDEFINE 2
Expected decision: Q4 2026 (company guidance)
PDUFA date: Not publicly confirmed
REDEFINE 4: NCT06131437 — non-inferiority not met
REDEFINE 1: 22.7% / 20.4% at 68 weeks
UK status: No MHRA authorisation

What an approval is actually assessed on

Whether a medicine is safe and effective for its proposed indication, judged largely against placebo-controlled evidence. That is what REDEFINE 1 and REDEFINE 2 provide. A comparative trial against a competitor answers a different question — how it ranks — which matters commercially and to prescribers rather than to the basic approvability decision.

So what did REDEFINE 4 change

The commercial picture rather than the regulatory one. A compound entering a market where the established option performed better in a direct comparison faces a harder argument with prescribers and payers, regardless of what its label says. That is a real consequence and it is not the same as a regulatory obstacle.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

Where the filing stands

Submitted to the FDA in December 2025 on the REDEFINE Phase 3 programme, with company guidance pointing to a decision in the fourth quarter of 2026. No PDUFA date has been publicly confirmed. If approved it would be the first once-weekly GLP-1 and amylin analogue combination for weight management.

Why the amylin approach is not settled by this

REDEFINE 4 compared a specific two-molecule combination at a specific dose pair against tirzepatide 15 mg. It did not test amylin as a mechanism. Single-molecule GLP-1 and amylin agonists such as amycretin are in Phase 3 development, and their results will speak to the target in a way this trial could not.

The UK position

CagriSema holds no MHRA authorisation and is not available in the UK. A US approval would not change that — the MHRA assesses separately, and UK availability additionally depends on NICE appraisal for NHS funding, which is a further and distinct process.

What none of this concerns

Research material. CagriSema is an investigational medicine under regulatory review, composed of two licensed-medicine components administered in registered trials. Nothing supplied here relates to it or is an alternative to any weight-management medicine.

Extended research context

The Research & Regulatory News deep dive

Deep dive: why 2026 was the year the incretin field split in two

For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction — the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer; it is separating into a convenience track and a magnitude track, and those tracks have different chemistry.

Deep dive: what a marketing authorisation actually means

An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.

Deep dive: reading trial results without being misled

Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.

Research applications

▸Tracking regulatory status of investigational incretin compounds
▸Understanding the difference between authorisation, NICE appraisal and NHS availability
▸Comparing peptide and non-peptide receptor agonist pharmacology
▸Interpreting Phase 3 topline releases before peer-reviewed publication
▸Verifying trial identity against ClinicalTrials.gov registrations

Handling checklist

✓Check the compound named in a trial registration matches the compound being discussed
✓Confirm the NCT identifier resolves to the acronym being cited
✓Read topline press releases as preliminary until peer-reviewed publication
✓Separate the trial population from the headline percentage before comparing studies
✓Treat authorisation in one jurisdiction as saying nothing about status in another

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating a positive Phase 3 as approval

Fix: Filing begins a review that commonly takes a year or more and can end in a request for more data.

✗ Comparing weight-reduction percentages across different trials

Fix: Population, duration and comparator differ; the numbers are not interchangeable.

✗ Assuming one incretin's approval legitimises another compound

Fix: Authorisations are product-specific and do not transfer between compounds.

✗ Citing a TRIUMPH number without checking the NCT identifier

Fix: Verify against ClinicalTrials.gov — the numbering has been widely misreported.

✗ Reading research material as an alternative to a licensed medicine

Fix: Research material is supplied for laboratory use only and is not a substitute for anything prescribed.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Does a failed head-to-head block approval?: No. Approval is assessed largely against placebo-controlled evidence, which REDEFINE 1 and 2 provide. A comparative trial answers a commercial question.
When is the FDA decision expected?: Company guidance points to the fourth quarter of 2026. No PDUFA date has been publicly confirmed.
Is CagriSema available in the UK?: No. It holds no MHRA authorisation, and a US approval would not change that.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Research & Regulatory News articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum